GSK announces positive headline results from EAGLE-1 phase III …
Feb 26, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea in adolescents and adults.
EAGLE-1 Phase III Data Show Potential for Gepotidacin as a New …
17 April 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults.
Gepotidacin accepted for priority review by US FDA for treatment …
3 days ago · Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years. Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents | GSK
GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial
3 days ago · GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.
Gepotidacin’s positive phase III data shows potential to be the ... - GSK
Apr 15, 2023 · Gepotidacin, discovered by GSK scientists, is an investigational bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different Type II topoisomerase enzymes.
Gepotidacin, a new first-in-class antibiotic for treating …
Feb 24, 2024 · Gepotidacin has the potential to be a valuable new treatment, which is particularly promising for patients who are resistant to other antibiotics or who are intolerant to first-line treatments.
GSK’s first-in-class antibiotic secures another phase III win ...
Mar 8, 2024 · GSK’s gepotidacin passed a phase III trial in uncomplicated urogenital gonorrhoea, providing activity against one of the WHO’s high-priority pathogens.
GSK’s Gepotidacin Shows Potential as First-In-Class Drug for ...
Apr 20, 2023 · Gepotidacin, an investigational oral antibiotic, for uncomplicated urinary tract infections (uUTIs) in female adolescents and adults, shows potential to be a new first-in-class drug for oral antibiotics with this indication, according to positive results from 2 phase 3 trials.
New antibiotic appears to be effective against urinary tract ... - CNN
Nov 4, 2022 · Drug company GSK said Thursday the new antibiotic, called gepotidacin, works at least as well as nitrofurantoin, a current front-line medication used to treat UTIs.
Gepotidacin accepted for priority review by US FDA for treatment …
Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years. Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents | GSK US